Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
PolyPeptide Group AG operates in the pharmaceutical industry, specializing in the development and manufacture of peptides for various applications. Headquartered in Zug, Switzerland, the company provides essential services and products for the pharmaceutical and biotechnology sectors, including custom peptide synthesis and generic peptide production. With a network of manufacturing facilities across Europe and the United States, PolyPeptide Group AG supports a global clientele. The company's strategic positioning is reinforced by its focus on innovation and quality, ensuring compliance with rigorous industry standards. PolyPeptide's competitive strength lies in its extensive expertise and capabilities in peptide synthesis, serving sectors ranging from therapeutic peptides to cosmetics.
View stock
VS
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
View stock

Stock highlights

Stock comparison highlights
Stock name
PolyPeptide Group AGEli Lilly
Last price
CHF 42.05$1,417.54
Currency
CHF
USD
CHF 1.4B$1.3T
103.1246.01
CHF 0.41$30.81
1.000.45
0$6.69
00.49%
Sector
HealthHealth
Employees
1,46050,000
Ticker
Fr. PPGN$LLY
Primary listing
XSWXNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in Fr.PPGN or $LLY on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.